Flok Health raises £9.5m led by Albion VC and Eka Ventures
This article covers Flok Health, a healthtech startup that has closed an oversubscribed series A funding round of £9.5m led by Albion VC. The funding will accelerate rollout of its NHS-integrated back pain service across the UK and extend its AI-operated physiotherapy clinic to new clinical pathways and geographies, supporting NHS providers, clinicians and patients with musculoskeletal conditions.
Flok Health, a healthtech startup that runs an AI-operated physiotherapy clinic, has closed an oversubscribed series A funding round of £9.5m led by Albion VC. The cash will be used to accelerate rollout of its NHS-integrated back pain service across the UK and to extend its AI clinic to new clinical pathways and geographies — a notable milestone given the regulatory approvals the company has already secured.
Why it matters
Musculoskeletal conditions are a leading cause of disability and lost work in the UK, with more than 30 million working days lost each year and over 390,000 people currently on waiting lists for MSK care in England. Digital interventions that can safely handle high-volume, routine pathways have the potential to free up clinician time for complex cases and reduce bottlenecks in the system. Flok’s NHS deployments claim reductions in waiting lists and substantial time savings for clinicians, making this funding round relevant for NHS providers, commissioners and healthtech investors watching how AI is operationalised in care.
Inside the product
Flok’s platform uses an AI system that plays manipulated footage of a human physiotherapist to simulate a live video consultation, responding in real time to what patients say and do. The service is delivered through a mobile app, offers on-demand appointments for back pain with no waitlist, and is currently available to more than 2.4 million patients across eleven NHS areas.
Two regulatory milestones underpin Flok’s commercial push. It is the first digital musculoskeletal service approved as a healthcare provider by the Care Quality Commission. It also claims to be the first AI system in Europe to achieve Class IIa medical device certification for autonomous delivery of full care pathways, permitting it to autonomously triage, treat and discharge patients within approved protocols. In recent NHS rollouts, more than 80% of patients reported the AI clinic was as good as or better than traditional in-person physiotherapy, and one Trust reported an average saving of 856 clinical hours per month.
The company says it is training the technology to manage hip and knee pain and women’s pelvic health, with all three new services due to launch in the UK this year. Once deployed, Flok estimates the expanded service could address conditions affecting more than 20 million people annually in the UK.
Who are the investors?
The series A was led by Albion VC, with participation from existing backers Eka Ventures and Form Ventures and new investor Mercia Ventures. The round was oversubscribed, signalling continued investor appetite for proven deployments of clinical AI.
In the announcement, Leigh Brody, Investor at Albion VC, said:
The supply-demand gap in healthcare is one of the defining challenges of our time. There are over 390,000 sitting on waiting lists in England for MSK conditions alone that are entirely treatable. What Finn, Ric and the team have done is demonstrate, with real patients in a real health system, that it's possible to deliver entire care pathways autonomously, at scale, without compromising on outcomes. They've navigated an extraordinarily complex regulatory environment, earned the trust of NHS partners, and built something that meets patients where they are, removing the practical barriers that often exclude the most vulnerable. That combination of clinical rigour, operational execution and patient impact is rare. MSK is where they've proven the model, but the opportunity ahead is far bigger. Having seen how this team operates, we have real confidence in their ability to deliver it.
If you're researching potential backers in this space:
- Explore our list of healthtech venture capital firms in the UK
- Browse our directory of healthtech angel investors in the UK
Founder perspective
Flok was founded in 2022 by Finn Stevenson, a former medic and athlete, and technologist Ric da Silva. The pair have positioned the product as a way to close the supply-demand gap in healthcare by automating high-volume pathways.
In the announcement, Finn Stevenson, Co-founder & CEO at Flok Health, said:
The most fundamental problem in healthcare today is supply-demand mismatch. Billions of people around the world suffer unnecessarily from treatable conditions, and it's just never going to be possible for traditional clinicians to solve this one patient at a time. AI is a generational opportunity to close that supply-demand gap and ensure that anyone, anywhere, can get the best possible care whenever they need it. We're particularly proud to already be scaling our AI MSK clinic in the NHS, and seeing incredible results for patients and services. This new funding will allow us to more rapidly scale our existing back pain service, and to expand the scope of our AI-operated clinic to fully manage new high volume clinical pathways, and new international markets.
Beyond the quote, the company says the new funds will support UK rollouts for hip, knee and pelvic health pathways and underwrite preparations for international expansion.
The bigger picture
Flok’s deal sits at the intersection of two trends: investor interest in healthtech that shows regulatory clearance and NHS integration, and a pragmatic focus on automation for routine care pathways. The company’s regulatory progress and reported NHS outcomes are material differentiators in a market where clinical validation and governance are central to adoption.
There are open questions for the sector about how autonomous AI services will be monitored in the long term, how liability and oversight are handled as services scale, and how NHS commissioners will evaluate cost and clinical effectiveness across diverse Trusts. Flok’s reported time savings and patient satisfaction data will be important evidence as commissioners decide whether to expand such services.
This funding round is another data point in the UK healthtech market showing that investors will back startups that combine clinical validation, regulatory approvals and NHS partnerships. As Europe continues to refine rules for medical AI, companies that can demonstrate safe, audited deployments in public health systems may gain an advantage in both domestic and international markets.
They've invested in Flok Health
Get to know these healthtech investors
| Investors | Investment Focus | Startup Investments | Round Size | Connect |
|---|---|---|---|---|
 AlbionVC( ) | ||||
 Eka Ventures( ) | ||||
 Mercia( ) | ||||
| All investors | All investor sectors | All funded startups | All funding rounds |
Click here for a full list of 7,589+ startup investors in the UK